SuperGen Presentations at AACR-NCI-EORTC

DUBLIN, Calif.--(BUSINESS WIRE)--Nov 9, 2009 - SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

SuperGen's presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776, SGI-110, SGI-1252, as well as two presentations on the Etk program. The posters will be made available for viewing on the company's website www.supergen.com following the respective presentations.

MP-470: The tyrosine kinase inhibitor MP470 inhibits RAD51-mediated homologous recombination and increases tumor cell radio- and chemosensitivity

 

Abstract A122, Monday Nov 16, 12:30 – 2:30 pm EST
 
SGI-110: In vivo activity of SGI-110, a novel hypomethylating agent for treatment in hematology and solid malignancies

 

Abstract A190, Monday Nov 16, 12:30 – 2:30 pm EST
 
MP-470: A self-emulsifying lipid suspension formulation enhances oral bioavailability of MP-470 in a randomized two-way crossover study in healthy male subjects

 

Abstract B209, Tuesday Nov 17, 12:30 – 2:30 pm EST
 
SGI-1776: The novel PIM kinase inhibitor SGI-1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma

 

Abstract B272, Tuesday Nov 17, 12:30 – 2:30 pm EST

 

 
ETK/BMX: Mechanistic, functional and in vivo efficacy of inhibiting ETK/BMX in cancer models

 

Abstract B263, Tuesday Nov 17, 12:30 – 2:30 pm EST
 
SGI-1252: In vivo activity of SGI-1252, a potent, small-molecule dual inhibitor of JAK2 and ALK2

 

Abstract C206, Wednesday Nov 18, 12:30 – 2:30 pm EST
 
ETK: Development of potent, small-molecule inhibitors of ETK

 

Abstract C199 Wednesday Nov 18, 12:30 – 2:30 pm EST
About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.

 

Contact: SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
tenns@supergen.com
Susanna Chau, 925-560-2845
Manager
Investor Relations
schau@supergen.com

 

Posted: November 2009

View comments

Hide
(web1)